Pharmacological options in the treatment of osteogenesis imperfecta: A comprehensive review of clinical and potential alternatives - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Biochemical Pharmacology Année : 2023

Pharmacological options in the treatment of osteogenesis imperfecta: A comprehensive review of clinical and potential alternatives

Résumé

Osteogenesis imperfecta (OI) is a genetically heterogeneous connective tissue disorder characterized by bone fragility and different extra-skeletal manifestations. The severity of these manifestations makes it possible to classify OI into different subtypes based on the main clinical features. This review aims to outline and describe the current pharmacological alternatives for treating OI, grounded on clinical and preclinical reports, such as antiresorptive agents, anabolic agents, growth hormone, and anti-TGFβ antibody, among other less used agents. The different options and their pharmacokinetic and pharmacodynamic properties will be reviewed and discussed, focusing on the variability of their response and the molecular mechanisms involved to attain the main clinical goals, which include decreasing fracture incidence, improving pain, and promoting growth, mobility, and functional independence.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée

Dates et versions

inserm-04100355 , version 1 (17-05-2023)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Javier Muñoz-Garcia, Dominique Heymann, Irina Giurgea, Marie Legendre, Serge Amselem, et al.. Pharmacological options in the treatment of osteogenesis imperfecta: A comprehensive review of clinical and potential alternatives. Biochemical Pharmacology, 2023, 213, pp.115584. ⟨10.1016/j.bcp.2023.115584⟩. ⟨inserm-04100355⟩
15 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More